A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
Latest Information Update: 21 Aug 2024
At a glance
- Drugs Guanfacine (Primary)
- Indications Behavioural disorders
- Focus Therapeutic Use
Most Recent Events
- 19 Aug 2024 Status changed from recruiting to completed.
- 13 Mar 2023 Planned End Date changed from 16 Feb 2023 to 18 Jan 2024.
- 13 Mar 2023 Planned primary completion date changed from 16 Feb 2023 to 18 Jan 2024.